These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 28619058)

  • 1. The regulatory role of DPP4 in atherosclerotic disease.
    Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
    Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.
    Zhong J; Kankanala S; Rajagopalan S
    Curr Opin Lipidol; 2016 Oct; 27(5):484-92. PubMed ID: 27472408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
    Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
    Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
    Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
    Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
    Remm F; Franz WM; Brenner C
    Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
    Zhong J; Rao X; Rajagopalan S
    Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.
    Gong Q; Rajagopalan S; Zhong J
    Int J Cardiol; 2015 Oct; 197():170-9. PubMed ID: 26142202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
    Mulvihill EE
    Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease.
    Akoumianakis I; Antoniades C
    Vascul Pharmacol; 2017 Sep; 96-98():1-4. PubMed ID: 28697993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
    Matteucci E; Giampietro O
    Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective role of DPP4 inhibitors in atherosclerosis.
    Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
    Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase 4/Midline-1 Axis Promotes T Lymphocyte Motility in Atherosclerosis.
    Rao X; Razavi M; Mihai G; Wei Y; Braunstein Z; Frieman MB; Sun XJ; Gong Q; Chen J; Zhao G; Liu Z; Quon MJ; Dong L; Rajagopalan S; Zhong J
    Adv Sci (Weinh); 2023 Mar; 10(9):e2204194. PubMed ID: 36683148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-dependent effects of dipeptidyl peptidase 4 inhibitors.
    Jackson EK
    Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):83-90. PubMed ID: 27898522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boning up on DPP4, DPP4 substrates, and DPP4-adipokine interactions: Logical reasoning and known facts about bone related effects of DPP4 inhibitors.
    Glorie L; D'Haese PC; Verhulst A
    Bone; 2016 Nov; 92():37-49. PubMed ID: 27535784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
    Mulvihill EE; Drucker DJ
    Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
    Panchapakesan U; Mather A; Pollock C
    Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway.
    Park DS; Kim K; Jang M; Choi SC
    BMB Rep; 2018 Dec; 51(12):636-641. PubMed ID: 30463640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
    Ohm B; Moneke I; Jungraithmayr W
    Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
    Huang J; Liu X; Wei Y; Li X; Gao S; Dong L; Rao X; Zhong J
    Front Immunol; 2022; 13():830863. PubMed ID: 35309368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice.
    Herman AB; Tsitsipatis D; Anerillas C; Mazan-Mamczarz K; Carr AE; Gregg JM; Wang M; Zhang J; Michel M; Henry-Smith CA; Harris SC; Munk R; Martindale JL; Piao Y; Fan J; Mattison JA; De S; Abdelmohsen K; Maul RW; Tanaka T; Moore AZ; DeMouth ME; Sidoli S; Ferrucci L; Liu Y; de Cabo R; Lakatta EG; Gorospe M
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37097759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.